Short Interest in Vincerx Pharma, Inc. (NASDAQ:VINC) Drops By 98.8%

Vincerx Pharma, Inc. (NASDAQ:VINC) was the target of a large decrease in short interest in the month of January. As of January 15th, there was short interest totalling 55,700 shares, a decrease of 98.8% from the December 31st total of 4,710,000 shares. Based on an average daily volume of 7,300,000 shares, the days-to-cover ratio is presently 0.0 days.

Wall Street Analyst Weigh In

Separately, Leerink Partners cut their price objective on Vincerx Pharma from $80.00 to $40.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 8th.

Institutional Trading of Vincerx Pharma

A hedge fund recently raised its stake in Vincerx Pharma stock. Marshall Wace LLP lifted its holdings in Vincerx Pharma, Inc. (NASDAQ:VINC) by 359.1% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 328,533 shares of the company’s stock after purchasing an additional 256,967 shares during the quarter. Marshall Wace LLP owned 1.11% of Vincerx Pharma worth $266,000 as of its most recent filing with the SEC. Institutional investors and hedge funds own 44.02% of the company’s stock.

Vincerx Pharma Price Performance

Vincerx Pharma stock traded down $0.06 during mid-day trading on Thursday, reaching $1.50. The company had a trading volume of 985,186 shares, compared to its average volume of 1,223,157. The stock’s 50-day simple moving average is $4.01 and its 200-day simple moving average is $8.84. The company has a market capitalization of $2.52 million, a P/E ratio of -1.46 and a beta of 1.48. Vincerx Pharma has a 1 year low of $1.40 and a 1 year high of $187.44.

Vincerx Pharma Company Profile

Vincerx Pharma, Inc, a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors.